Patents by Inventor Nils WILLISTON

Nils WILLISTON has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immunogenic composition comprising a fusion peptide derived from superantigen toxoids
    Patent number: 11826412
    Abstract: The present disclosure provides immunogenic compositions useful in prevention and treatment of Staphylococcus aureus infection. In particular, the disclosure provides multivalent oligopeptides, fusion proteins comprising two or more staphylococcal superantigen (SAg) proteins, or any fragments, variants, or derivatives thereof fused together as a single polypeptide in any order.
    Type: Grant
    Filed: February 25, 2022
    Date of Patent: November 28, 2023
    Assignee: ABVACC, Inc.
    Inventors: Mohammad Javad Aman, Thomas Kort, Arundhathi Venkatasubramaniam, Nils Williston, Rajan Prasad Adhikari, Frederick W. Holtsberg
  • Immunogenic compositions comprising leukocidin LukA and LukB derived polypeptides
    Patent number: 11421021
    Abstract: The present disclosure provides immunogenic compositions useful in prevention and treatment of Staphylococcus aureus infection. In particular, the disclosure provides methods of inducing an immune response against a LukAB-expressing S. aureus, methods of preventing or treating S. aureus infections, and composition for preventing or treating S. aureus infections.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: August 23, 2022
    Assignee: INTEGRATED BIOTHERAPEUTIC VACCINES, INC.
    Inventors: Thomas Kort, Nils Williston, Shweta Kailasan, Hatice Karauzum, Rajan P. Adhikari, Mohammad Javad Aman
  • IMMUNOGENIC COMPOSITION COMPRISING A FUSION PEPTIDE DERIVED FROM SUPERANTIGEN TOXOIDS
    Publication number: 20220257744
    Abstract: The present disclosure provides immunogenic compositions useful in prevention and treatment of Staphylococcus aureus infection. In particular, the disclosure provides multivalent oligopeptides, fusion proteins comprising two or more staphylococcal superantigen (SAg) proteins, or any fragments, variants, or derivatives thereof fused together as a single polypeptide in any order.
    Type: Application
    Filed: February 25, 2022
    Publication date: August 18, 2022
    Inventors: Mohammad Javad AMAN, Thomas KORT, Arundhathi VENKATASUBRAMANIAM, Nils WILLISTON, Rajan Prasad ADHIKARI, Frederick W. HOLTSBERG
  • Immunogenic composition comprising a fusion peptide derived from superantigen toxoids
    Patent number: 11260120
    Abstract: The present disclosure provides immunogenic compositions useful in prevention and treatment of Staphylococcus aureus infection. In particular, the disclosure provides multivalent oligopeptides, fusion proteins comprising two or more staphylococcal superantigen (SAg) proteins, or any fragments, variants, or derivatives thereof fused together as a single polypeptide in any order.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: March 1, 2022
    Assignee: INTEGRATED BIOTHERAPEUTIC VACCINES, INC.
    Inventors: Mohammad Javad Aman, Thomas Kort, Arundhathi Venkatasubramaniam, Nils Williston, Rajan Prasad Adhikari, Frederick W. Holtsberg
  • IMMUNOGENIC COMPOSITIONS COMPRISING STAPHYLOCOCCUS AUREUS LEUKOCIDIN LUKA AND LUKB DERIVED POLYPEPTIDES
    Publication number: 20200317759
    Abstract: The present disclosure provides immunogenic compositions useful in prevention and treatment of Staphylococcus aureus infection. In particular, the disclosure provides methods of inducing an immune response against a LukAB-expressing S. aureus, methods of preventing or treating S. aureus infections, and composition for preventing or treating S. aureus infections.
    Type: Application
    Filed: June 13, 2018
    Publication date: October 8, 2020
    Inventors: Thomas KORT, Nils WILLISTON, Shweta KAILASAN, Hatice KARAUZUM, Rajan P. ADHIKARI, Mohammad Javad Aman
  • IMMUNOGENIC COMPOSITION COMPRISING A FUSION PEPTIDE DERIVED FROM SUPERANTIGEN TOXOIDS
    Publication number: 20200206335
    Abstract: The present disclosure provides immunogenic compositions useful in prevention and treatment of Staphylococcus aureus infection. In particular, the disclosure provides multivalent oligopeptides, fusion proteins comprising two or more staphylococcal superantigen (SAg) proteins, or any fragments, variants, or derivatives thereof fused together as a single polypeptide in any order.
    Type: Application
    Filed: July 25, 2018
    Publication date: July 2, 2020
    Inventors: Mohammad Javad AMAN, Thomas KORT, Arundhathi VENKATASUBRAMANIAM, Nils WILLISTON, Rajan Prasad ADHIKARI, Frederick W. HOLTSBERG